 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- | umbilical cord mesenchymal stem cell therapy (hUC-MSC) / Shenzhen Beike Biotech
Journal, Stroma: A GMP-compliant manufacturing method for Wharton's jelly-derived mesenchymal stromal cells. (Pubmed Central) - May 4, 2024
Our scalable manufacturing processes facilitate the large-scale production of high-quality WJ-MSCs. These findings contribute to the advancement of WJ-MSCs-based therapies in regenerative medicine.
- | umbilical cord mesenchymal stem cell therapy (hUC-MSC) / Shenzhen Beike Biotech
Journal, Heterogeneity: Unveiling the functional heterogeneity of cytokine-primed human umbilical cord mesenchymal stem cells through single-cell RNA sequencing. (Pubmed Central) - Mar 27, 2024
These findings contribute to the advancement of WJ-MSCs-based therapies in regenerative medicine. These findings contribute to a comprehensive understanding of the inflammatory priming of MSCs, paving the way for their precise treatment in clinical applications.
- | umbilical cord mesenchymal stem cell therapy (hUC-MSC) / Beike Biotech
Journal: Interleukin-18-primed human umbilical cord-mesenchymal stem cells achieve superior therapeutic efficacy for severe viral pneumonia via enhancing T-cell immunosuppression. (Pubmed Central) - Jan 29, 2023
Notably, IL18-hUCMSC treatment has a superior inhibitory effect on T-cell exudation and proinflammatory cytokine secretion in bronchoalveolar lavage fluid (BALF). Altogether, IL-18 is a promising cytokine that can prime hUC-MSCs to improve the efficacy of precision therapy against viral-induced pneumonia, such as COVID-19.
- || umbilical cord mesenchymal stem cell therapy (hUC-MSC) / Beike Biotech
P1 data, Retrospective data, Clinical Trial,Phase I, Journal: Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up. (Pubmed Central) - Sep 14, 2022
Based on the current pilot study, the preliminary clinical benefits of hUC-MSCs on DFU healing were shown, including good tolerance, a shortened healing time to 1.5 months and a favorable 3-year amputation-free survival rate. The clinical evidence in the current study suggested a further phase I/II study with a larger patient population and a more rigorous design to explore the efficacy and mechanism of hUC-MSCs on DFU healing.
- | umbilical cord mesenchymal stem cell therapy (hUC-MSC) / Beike Biotech
Preclinical, Journal: Reproductive and Developmental Toxicity Assessment of Human Umbilical Cord Mesenchymal Stem Cells in Rats. (Pubmed Central) - Jun 8, 2022
Based on the results of the studies, the no-observed-adverse-effect levels (NOAELs) are 8.5 × 10/kg for fertility and early embryonic development, 1.2 × 10/kg for maternal toxicity and 2.4 × 10/kg for embryo-fetal development in rats intravenous injected with hUC-MSCs, which are equivalent to 8.5-fold, 12-fold, and 24-fold respectively of its clinical dosage in humans. These findings may provide a rational basis for human health risk assessment of hUC-MSCs.
- | umbilical cord mesenchymal stem cell therapy (hUC-MSC) / Beike Biotech
Preclinical, Journal: Human umbilical cord-derived mesenchymal stem cells improve the function of liver in rats with acute-on-chronic liver failure via downregulating Notch and Stat1/Stat3 signaling. (Pubmed Central) - Aug 8, 2021
These findings may provide a rational basis for human health risk assessment of hUC-MSCs. hUC-MSC transplantation can improve liver function, the degree of fibrosis, and liver damage and promote liver repair in rats with ACLI or ACLF, mediated most likely by inhibiting Notch signaling and reversing the imbalance of the Stat1/Stat3 pathway.
- | umbilical cord mesenchymal stem cell therapy (hUC-MSC) / Beike Biotech
Journal: Human umbilical cord mesenchymal stromal cells attenuate pulmonary fibrosis via regulatory T cell through interaction with macrophage. (Pubmed Central) - Aug 8, 2021
Our study establishes a link between hucMSCs, macrophage, Treg, and PF. It provides new insights into how hucMSCs interact with macrophage during the repair process of bleomycin-induced PF and play its immunoregulation function.